Is the overall survival for older adults with AML finally improving?

Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Jeffrey E. LancetAbstractOlder adults with acute myeloid leukemia (AML) traditionally have very poor survival outcomes. Those who receive only supportive care have worse overall survival than those who undergo treatment, regardless of treatment type, and improvements in overall survival in the last several decades are largely attributable to the increasing decision to treat rather than offer only supportive care. However, there are a few newer agents that appear promising; these include CPX-351 (a liposomal product with cytarabine and daunorubicin), glasdegib (a selective Hedgehog signaling pathway inhibitor), and venetoclax (potent small molecule inhibitor of BCL2). A systematic review and meta-analysis is being completed to help clinicians optimize standard therapies for older AML patients.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research